Advocates Criticize US Government’s Settlement Of Lawsuit Against Gilead Over Billions In Profits Tied To HIV Drug Patents

Bloomberg Law (1/21, Yasiejko, Subscription Publication) reports, “Public health advocates expressed outrage at the US government’s settlement of its lawsuit against Gilead Sciences Inc. over billions in profits tied to HIV drug patents, arguing the deal shortchanges taxpayers and sets a troubling precedent for government-funded innovation.” Last week’s agreement, “which ended a five-year legal battle, granted Gilead a license to key government-owned patents related to pre-exposure prophylaxis, known as PrEP, for preventing the transmission of HIV.”